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ABSTRACT  28 
Strongyloidiasis is an intestinal parasitic infection becoming increasingly important 29 
outside endemic areas, not only because of the high prevalence found in migrant 30 
populations, but also because immunosuppressed patients may suffer a potentially fatal 31 
disseminated disease. The aim of these guidelines is to provide evidence-based guidance 32 
for screening and treatment of strongyloidiasis in non-endemic areas. A panel of experts 33 
focused on three main clinical questions (who should be screened and how, how to 34 
treat), and reviewed pertinent literature available in international databases of medical 35 
literature and in documents released by relevant organizations/societies. A consensus of 36 
the experts’ opinion was sought when specific issues were not covered by evidence. In 37 
particular, six systematic reviews were retrieved and constituted the main support for 38 
this work. The evidence and consensus gathered led to recommendations addressing 39 
various aspects of the main questions. Grading of evidence and strength of 40 
recommendation were attributed to resume the quality of supporting evidence. 41 
The screening of individuals at risk of the infection should be performed before they 42 
develop any clinical complication.  Moreover, in immunosuppressed patients, the 43 
screening should be mandatory. The screening is based on a simple and widely 44 
accessible technology and there is now a universally accepted treatment with a high 45 
efficacy rate. Therefore, the screening could be implemented as part of a screening 46 
program for migrants although further cost-effectiveness studies are required to better 47 






Strongyloidiasis is a parasitic disease widely distributed in tropical and subtropical 52 
regions
1
, with over 350 million people estimated to be infected worldwide.
2
 Migrant 53 
populations living in European countries present a high risk of having 54 
strongyloidiasis,
3,4
 and it has been reported that the prevalence in immigrants may range 55 
from 2 to 46%,
5
 but few studies have assessed the burden and risk factors of imported 56 
strongyloidiasis
3,6
.  57 
The infection has three peculiar characteristics that are of importance from the clinical 58 
and public health point of view: Firstly, more than half of infected subjects are 59 
asymptomatic or have mild, not specific complains,
6
 and eosinophilia is often the only 60 
finding.
4
 Therefore they are usually unaware that they might harbour an infection
7
. 61 
Secondly, S.stercoralis has the ability to replicate indefinitely inside the host 62 
(autoinfective cycle) without any further exposure to an infected site, thus causing a 63 
lifelong infection if left untreated.
8,9
  Thirdly, immunosuppressed patients can develop 64 
the hyperinfection syndrome or the disseminated disease, which has a fatality rate of 60-65 
70%.
10
  The most frequent trigger of this complication is a chronic therapy with 66 
steroids, but solid organ or bone-marrow transplant recipients, patients with 67 
malignancies, or those under therapy with immunosuppressive drugs are also at risk.
11
 68 
Human T-Cell Lymphotropic virus 1 (HTLV-1) is also a risk factor for severe disease 69 
and treatment failure.
12,13
    70 
. The rationale for a screening of S. stercoralis in non-endemic countries is based on the 71 
high estimated prevalence of the infection among migrants, the availability of a 72 
sensitive method for detection, and the potential to prevent fatal complications through 73 
early case detection. Currently, a few societies/organizations recommend screening for 74 
4 
 
S.stercoralis in specific fields, like solid organ transplantation
14
 since it has been 75 
recognised that strongyloidiasis can be acquired from an infected donor.
15–17
 76 
Different screening strategies include universal screening (when all individuals in a 77 
certain category are tested,
18
) and case finding (when only a well-defined group with 78 
risk factors are candidates for screening.
19
).   79 
 80 
OBJECTIVES 81 
These guidelines are aimed to provide evidence-based guidance and, when not 82 
available, consensus opinion from a group of experts to address the screening and 83 
treatment of strongyloidiasis in non-endemic areas. 84 
 The following definitions were used in these guidelines: 85 
1. Individuals with high risk of exposure to S. stercoralis: immigrants coming from 86 
endemic areas (Africa, Latin-America, Asia and Oceania), adopted children who 87 
have been living for at least one year in highly endemic area, expatriates (i) 88 
undertaking long trips (more than one year) to endemic countries and (ii) with 89 
exposure to rural areas. 90 
2. Individuals with intermediate - low risk of exposure to S. stercoralis:  short-term 91 
(less than one year) travellers to highly endemic areas; elderly patients living in 92 
countries where transmission was occurring in the past, which include Northern 93 
Italy
20
 and the Spanish Region of Valencia.
21
   94 
3. Immunosuppressed: patients in chronic treatment with corticosteroids, 95 
chemotherapy, immunosuppressant and immunomodulator agents, transplant 96 




4. Candidates to immunosuppression: candidates to immunosuppressant therapies 99 
(see above), candidates to solid or bone marrow transplant. Patients with well-100 
controlled HIV infection should be managed like non-immunosuppressed 101 
individuals.  102 
5. Disseminated strongyloidiasis: severe infection with presence of parasites outside 103 
the classical life cycle (ie, in organs other than the skin, gastrointestinal tract, lungs). 104 
6. Strongyloides hyperinfection: increase in the number of larvae in the stools and/or 105 
sputum along with clinical manifestations limited to the respiratory and 106 
gastrointestinal systems, and peritoneum. 107 
 108 
2.METHODS 109 
Panel composition 110 
We convened a panel of six experts, all of them specialists in migrant health and 111 
imported diseases, with a particular experience in strongyloidiasis.   112 
The panel addressed the following 3 clinical questions: 113 
(i) Who should be screened? 114 
(ii) How to screen strongyloidiasis 115 
(iii) How to treat strongyloidiasis 116 
  117 
Literature review and analysis 118 
Panel members thoroughly reviewed the literature pertinent to each of the question 119 
using Pubmed /Medline, and Cochrane library. 120 
They particularly evaluated the results of four recent systematic reviews (SRs) about 121 
strongyloidiasis published by the COHEMI-project. All these SRs had been undertaken 122 
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by five members of the panel. The COHEMI project comprehensively reviewed 123 
different aspects of strongyloidiasis and the final results were four SRs published in 124 
peer-reviewed journals
3,7,10,22
 and another study that evaluated the accuracy of five 125 




Moreover, other SRs on strongyloidiasis have been additionally included for the 128 
guidelines development. For this purpose, panel members thoroughly reviewed the 129 
literature pertinent to each of the question using Pubmed/Medline, Embase, CINAHL, 130 
Cochrane CENTRAL, as well as grey literature for other relevant documents as well as 131 
published guidelines and reports on screening for strongyloidiasis in relevant 132 
organizations (e.g., ECDC, WHO) databases. 133 
 134 
Process overview 135 
In creating the guidelines, the panel applied the same principles as the Agency for 136 
Healthcare Research and Quality (AHRQ)
25
.   137 
This included the available evidence based on the SRs and the grading of the 138 
recommendations. The panel members reviewed each recommendation, their strengths 139 
and the quality of evidence. Discrepancies were discussed and resolved, in order to 140 
achieve a consensus for each recommendation. The strength assigned to a 141 
recommendation reflects the panel’s confidence that the benefits of following the 142 
recommendation are likely to outweigh potential harms.  143 
Grading of evidence 144 
 Ia: systematic review or meta-analysis of randomized controlled trials (RCTs). 145 
 Ib: at least one RCT. 146 
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 IIa: at least one well-designed controlled study without randomization. 147 
 IIb: at least one well-designed quasi-experimental study, such as a cohort study. 148 
 III: well-designed non-experimental descriptive studies, such as comparative 149 
studies, correlation studies, case-control studies and case series. 150 
 IV: expert committee reports, opinions and/or clinical experience of respected 151 
authorities. 152 
Grading of recommendations 153 
 A: based on hierarchy I evidence. 154 
 B: based on hierarchy II evidence or extrapolated from hierarchy I evidence. 155 
 C: based on hierarchy II evidence or extrapolated from hierarchy I or II 156 
evidence. 157 
 D: directly based on hierarchy IV evidence or extrapolated from hierarchy I, II 158 
or III evidence 159 
3. RESULTS 160 
Six systematic reviews have been finally included (see table 1) 161 
(i)Who should be screened? 162 
First, epidemiological data are important to identify patients at risk of exposure to 163 
S.stercoralis. However, there is limited evidence in the literature providing prevalence 164 
data of strongyloidiasis. In one systematic review about imported strongyloidiasis, 165 
prevalence ranged from 0.4-46%, which varied depending on the diagnostic technique 166 
used and the targeted population (migrant and/or refugees)
26
.  Another systematic 167 
review suggests that S.stercoralis affects between 10 and 40% of the population in most 168 
tropical and subtropical countries
5
;  this study also estimates high infection rates in 169 
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refugees and migrants living in non-endemic areas, reaching prevalences up to 75%.
5
.  170 
However, infection rates varied substantially depending on the refugees’ country of 171 
origin  and the studies analyzed suggest that the infection may be underreported, 172 
especially in Sub-Saharan Africa and South-East Asia
5
.    173 
Second, we should differentiate between (i) patients with high risk of exposure to 174 
S.stercoralis and (ii) patients with intermediate-low risk of exposure, as defined 175 
previously.  176 
Moreover, the risk of developing a severe disease is not the same in all patients 177 
harbouring the infection. Most infected subjects will never incur in the complicated 178 
form throughout their life,
8
 while immunocompromised patients are at risk of 179 
developing a severe, life-threatening disease.
10
 180 
Therefore, when considering the screening for S.stercoralis, we should differentiate two 181 
clinical situations.  Immunocompetent patients.  182 
The economic benefits of soil-transmitted infections screening in asymptomatic 183 
immunocompetent individuals, both in cost per hospitalization averted and disability-184 
adjusted life years (DALYs), have been evaluated through cost-effectiveness studies 185 
conducted in the United States.
27,28
  186 
The results of these economic analyses showed that universal screening and 187 
presumptive antiparasitic treatment were more cost-effective strategies to control soil-188 
transmitted helminths in immigrants entering United States, compared to a “watchful 189 
waiting” strategy.
27
 However, these studies did not consider serology as a screening 190 
method, nor new data about the efficacy of ivermectin for the treatment of 191 
strongyloidiasis.
29
  192 
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Testing for S.stercoralis has been suggested only for patients with eosinophilia (>500 193 
eosinophils-per-microliter of blood) returning from the tropics.
30
 Eosinophilia is a 194 
frequent (48-78%) finding in patients with strongyloidiasis, 
31–33
 but clearly, its absence 195 
does not exclude the infection.
22
 It is a too weak predictor of strongyloidiasis in 196 
migrants.
22,34,35
  197 
Hence, strongyloidiasis should be ruled out in any individual at risk of the infection and 198 
with eosinophilia as part of the differential diagnosis of eosinophilia. However, a two-199 
steps screening strategy (blood count and serological-test if eosinophilia is present) is 200 
not recommended considering a) the need of two accesses of the patient to the lab; b) 201 
the insufficient sensitivity of eosinophilia.  202 
Recommendations. Immunocompetent patients who present high risk of exposure 203 
to S. stercoralis infection should be routinely screened for strongyloidiasis.  204 
Grading of evidence: III 205 
Grading of recommendations: D. 206 
Immunosuppressed patients/ candidates to immunosuppression (see “Definitions”).   207 
People exposed to immunosuppressant conditions should be particularly targeted due to 208 
the increased risk of developing severe disease which has a high mortality rate.
10,36
 A 209 
study which evaluated the risk factors for developing strongyloidiasis hyperinfection, 210 
concluded that all patients with severe disease were immunocompromised.
37
 As it has 211 
already been mentioned, a wide variety of predisposing factors has been described: 212 
hematologic malignancies, transplantation, immunosuppressant drugs. Steroids remain 213 
the most frequent risk factor for developing severe disease, which has been reported 214 
even during short steroid courses.
37,38
 It is difficult to quantify the risk of developing 215 
hyperinfection or disseminated disease in case of immunosuppression and also the 216 
amount of risk of complication involved in each particular type of immunosuppression 217 
10 
 
is unknown. To sum up, immunosuppression poses the patients at risk of developing the 218 
severe disease, then it has been recommended to screen the patients for S.stercoralis 219 
before administering immunosuppressant therapy, as well as before transplantation or 220 
other immunosuppressant conditions.
10
  221 
Finally, and considering the high efficacy and tolerability of ivermectin, it might be 222 
probably worth treating high – risk patients pre-emptively in case an appropriate test 223 
(stool culture or serology) is not available.
10
 224 
Recommendations. Immunosuppressed patients and candidates to  225 
immunosuppression should be routinely screened for strongyloidiasis if they have 226 
high or intermediate risk of exposure to S.stercoralis.  227 
If an appropriate diagnostic test is not available, specific treatment with 228 
ivermectin should be pre-emptively provided. 229 
Grading of evidence: Ia 230 
Grading of recommendations: B 231 
 232 
(ii) How to screen? 233 
The diagnosis of S. stercoralis infection is hampered by the low sensitivity of fecal-234 
based tests and the suboptimal specificity of most serological test.
22
  235 
Direct methods (parasitological-based methods) 236 
A single stool examination fails to detect S. stercoralis larvae in up to 70% of cases. 237 
Repeated examinations of stool specimens improve the chances of finding parasites; in 238 
some studies, diagnostic sensitivity increases to 50% with 3 stool examinations.
39,40
 239 
 A recent meta-analysis on the evaluation of conventional parasitological methods found 240 
the highest sensitivity (89%) for agar plate culture, followed by the Baermann technique 241 
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(72%), FECT (48%), and direct wet smear (21%).
41
 In most of the diagnostic studies on 242 
strongyloidiasis, the reference standard used was based on faecal methods.
22
 However, 243 
the sensitivity of any faecal-based reference standard may be sub-optimal, especially in 244 
chronic infections where larval output is often very low. 245 
Indirect methods (serology) 246 
Serological methods are the most sensitive available diagnostic tools. There are several 247 
serologic tests that demonstrated better sensitivity compared to stool methods.
42–49
 248 
However, false negative results occur, especially in acute infections
50
 and in 249 
immunosuppressed patients
22,33,51,52
 and false positive can occur due to other helminthic 250 
infection, especially nematodes.
23
  251 
A diagnostic accuracy trial has evaluated five different serological tests for 252 
S.stercoralis, including the two commercially available Bordier-ELISA and IVD-253 
ELISA.
23
 The two latter tests showed a high sensitivity andspecificity: 91.2% and 254 
99.1% for IVD-ELISA, 89.5% and 98.3% for Bordier ELISA.   255 
Recommendation 256 
Screening should be performed with a highly sensitive serological test. If not 257 
available, improved faecal techniques could also be used (Baerman or APC).  258 
Grading of evidence: Ia 259 
Grading of recommendations: B 260 
Recommendation 261 
In immunosuppressed patients, a combination of serological and parasitological 262 
methods (see above) is mandatory, and screening should be performed before the 263 
immunosuppression if possible; first to avoid the risk of severe disease and second 264 
12 
 
because serology is less sensitive once immunosuppression has already been 265 
established. 266 
Grading of evidence: III 267 
Grading of recommendations: D 268 
COHEMI recommendations for screening are resumed in figure 1. 269 
 270 
(iii) How to treat? 271 
A recent Cochrane systematic review has reported a higher cure rate of strongyloidiasis 272 
with ivermectin compared with albendazole and a better tolerance. Similar cure rates 273 
were observed when ivermectin was compared with thiabendazole but more adverse 274 
events were reported with the second drug
53
.  275 
Most trials were relatively small, with less than 100 patients per arm. All trials but one 276 
exclusively relied on faecal diagnostic methods for the assessment of cure. 277 
The main findings of the trials are summarized in Table 2 (that includes also trials not 278 
considered in the Cochrane review). The number needed to treat (NNT) was also 279 
calculated for each trial. 280 
Albendazole versus placebo. A double blind, placebo controlled trial evaluated the 281 
efficacy of albendazole for several intestinal helminths, including S.stercoralis at the 282 
dose of 400 mg daily for three consecutive days, and showing a cure rate of 48%.
54
  283 
Albendazole at high dosage. A randomized controlled trial comparing two different, 284 
high dosage schedules of albendazole, showed an efficacy of 87.9% for albendazole 285 
(800 mg twice-daily three days) and 89.5% for albendazole (800 mg twice-daily five 286 
days)   no significant difference).
55
  287 
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Albendazole versus ivermectin. Six RCT were carried out from 1994 to 2011, on 288 
ivermectin single standard dose for one or two days, versus albendazole at different 289 
dose schedules, including high dosage. All invariably showed a superiority of 290 
ivermectin, with cure rates ranging from 83-100% for the latter, and from 38-79% for 291 
albendazole.
56–60
  292 
Albendazole versus thiabendazole. We retrieved a single RCT
61
 reporting a similar high 293 
cure rate for albendazole at high dose (800 mg daily for 5 consecutive days, with cure 294 
rate 95%) and thiabendazole (1g twice daily for 5 days, with cure rate 100%). The 295 
sample size of this study was particularly small, with 35 patients enrolled overall and a 296 
short duration of follow up (21 days).  297 
Thiabendazole versus ivermectin. Three RCT compared the two drugs,
62–64
 all 298 
demonstrating equivalent efficacy and a much higher incidence of untoward effects for 299 
thiabendazole.  300 
Recommendations.  301 
Chronic (uncomplicated) strongyloidiasis should be treated with ivermectin. 302 
Grading of evidence: Ia 303 
Grading of recommendations: A 304 
At the moment, the recommended dosage is a stat dose of 200 µg/kg (as reported in the 305 
patient information leaflet), although some authors suggest that multiple doses might 306 
increase the efficacy.
65
 The World Health Organization (WHO) model drug formulary
66
 307 
gives both options: one day versus two consecutive days, single dose. Two trials 308 
compared the two different regimens of ivermectin, the first one published in 1994
62
 309 
and with small numbers reported a cure rate of 100% with both schemes, while the 310 
second and more recent one,
60
  reported a slightly higher cure rate (not statistically 311 
significant) for the single dose (97% versus 93%). A multicentre RCT is currently 312 
14 
 




Empiric treatment.   315 
In case adequate laboratories facilities are not available, and the infection cannot be 316 
excluded, empiric treatment might be worth, in consideration of the good tolerability of 317 
the drug and the potential harm caused by a missed diagnosis.
65
  This is particularly 318 
advised for patients who are candidate to be immunosuppressed, such as, but not limited 319 
to, transplant recipients.
68
   320 
Recommendation. Empiric treatment of patients at risk of immunosuppression, if 321 
past exposure cannot be excluded, is indicated without testing in case of lack of 322 
adequate diagnostic facilities (see the section “How to screen”).  323 
Grading of evidence: IV 324 
Grading of recommendations: D 325 
 326 
Follow up after treatment 327 
Evidence summary 328 
A post-treatment evaluation with parasitological methods does not reliably exclude the 329 
infection, as the sensitivity of these methods is low. Several studies have reported that 330 
the serologic titer usually tends to decrease after treatment,
48,64,69–71
 but uniform criteria 331 
to define cure have not been established.
22,42
 Recently, it has been shown that, for all of 332 
the five tests analyzed by a diagnostic study (three ELISA tests, one LIPS and one 333 
IFAT), the OD/luminescence/titre consistently showed a diminishing trend with time, 334 
tending to negativization, for the cases treated successfully, although the time required 335 
may be as long as 12 months or more.
24
 Failure to achieve a significant reduction in titer 336 
or OD (to 50% or less of the OD prior to treatment, or at least two IFAT dilutions) 337 
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should be considered as a potential treatment failure, even if faecal-based tests are 338 
negative.   339 
Recommendations. Post treatment follow up should be performed with the most 340 
sensitive technique available. Serology should be done at baseline and repeated 341 
after 6 and 12 months after treatment to monitor the decrease in OD/titer or 342 
negativization.   343 
Grading of evidence: IIb 344 
Grading of evidence: C 345 
DISCUSSION 346 
 The rationale for the implementation of a screening programme should be based on the 347 
classical 10 principles of Wilson and Jungner
72
.  There are several reasons that justify 348 
the screening in asymptomatic people.  349 
 In the first place, an early detection of the infection in individuals at risk, before they 350 
develop any clinical complication, is in itself a sufficient argument to propose a 351 
screening. Moreover, in immunosuppressed patients, the screening should be 352 
mandatory. Secondly, there is a drug, ivermectin, which is now the universally accepted 353 
treatment with a high efficacy rate and a low rate of adverse effects. Thirdly, the 354 
screening is based on a simple and widely accessible technology, including 355 
commercially available tests which are highly sensitive. The screening could be 356 
implemented as part of a screening program for migrants, although further cost-357 
effectiveness studies are required to better evaluate this strategy from a public health 358 
point of view.  359 
  360 
  361 
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Table 1. systematic reviews finally included 720 
 721 
Title Author Year Topic on 
strongyloides 
Reference 
Imported strongyloidiasis: epidemiology, 
presentations, and treatment 
Buonfrate D 2012 Prevalence 
26
 
Prevalence of strongyloidiasis in Latin America: 
a systematic review of the literature 
Buonfrate D 2015 Prevalence 
7
 
Strongyloides stercoralis: Global Distribution 
and Risk Factors.  
Schar 2013 Prevalence 
5
 
The laboratory diagnosis and follow up of 














Ivermectin versus albendazole or thiabendazole 









Table 2. Summary of published trials of strongyloidiasis treatment 
Author Drug(s), dose Diagnostic methods  Cured (%) NTT p-value Ref 





Albendazole 400 mg/d x 3 d 12/25 (48%) 
Singthong Albendazole 800 mg bid for 3 d repeated 
after 1 w 





Albendazole 800 mg bid for 5 d repeated 
after 1 w 
51/58 (89.5%) 
Datry Albendazole 400 mg/d x 3 d Fecal smear, Kato, FECT / 
Baermann  





Ivermectin 150-200 µg/kg single dose 24/29 (83%) 
Marti Albendazole 400 mg/d x 3 d Baermann method / Kato-
Katz 





Ivermectin 200 µg/kg single dose 126/152 (83%) 
Toma Albendazole 800 mg bid for 3 d Harada-Mori  
APC 









Ivermectin 6 mg single dose 65/67 (97.0%) 
Pyrvinium pamoate 5 mg/kg for 3 d 14/60 (23.3%) 
Nontasut Albendazole 400 mg bid for 5 d Kato-Katz culture, APC 26/33 (78.8%) 5 <0.01 
59
 
Ivermectin 200 µg/kg single dose 77/78 (98-7%) 
Suputtamongkol Albendazole 800 mg/d x 7 d FECT 8/21 (38.1%) 2.625 0.029 
73
 
Ivermectin 200 µg/kg single dose 16/21 (76.2%) 





Ivermectin 200 µg/kg single dose for 2 d 27/29 (93.1%) 3.6 
Albendazole 800 mg/d x 7 d 19/30 (63.3%) --- 
  Albendazole 400 mg bid for 5 d Fecal smear, Harada-Mori, 
larva count (Stool and Sasa 
method) 
22/23 (95%) 23   
Thiabendazole 1 g bid for 5 d 12/12 (100%) 
Gann Ivermectin 200 µg/kg single dose  Baermann 16/16 (100%) 19 NS 
62
 
Ivermectin 200 µg/kg single dose for 2 d 18/18 (100%) 19 
Thiabendazole 25 mg/kg bid for 3 d 18/19 (94.7%) --- 
Adenusi Ivermectin 200 µg/kg single dose  Baermann 95/113 (84.1%) 18.4 NS 
63
 
Thiabendazole 25 mg/kg bid for 3 d 81/103 (78.6%)  
Bisoffi Ivermectin 200 µg/kg single dose  APC, serology (IFAT) 32/47 (68.1%)  NS 
29
 





Figure 1. Algorithm diagnosis of screening  
* Serology is preferable but if not available, improved faecal techniques could also be used 
(Baerman or APC).   
** When serology or more sensitive stool techniques (Baermann or stool culture) is not 
available, consider empiric treatment with ivermectin  
 
Con formato: Fuente: Calibri, 11 pto,
Sin Negrita
